On March 1, 2019 Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, reported that its Phase 1 clinical trial evaluating COM701, a first-in-class therapeutic antibody targeting PVRIG, was featured in a trial-in-progress at The ASCO (Free ASCO Whitepaper)-SITC Clinical Immuno-Oncology Symposium (Press release, Compugen, MAR 1, 2019, View Source [SID1234533881]). In poster titled "A Phase 1 Study Evaluating COM701 in Patients With Advanced Solid Tumors," the Company reported that the third single subject dose cohort has been completed with no dose-limiting toxicities (DLTs) reported. Clinical and laboratory assessment for safety and tolerability is ongoing for the fourth dosing cohort. The poster presented at the symposium is available on Compugen’s website.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We continue to see significant interest in the study from investigators as they recognize the potential and differentiation of COM701 relative to other checkpoint inhibitors in development," said Henry Adewoye, M.D., Chief Medical Officer at Compugen. "After recently adding Massachusetts General Hospital and the University of Chicago, two additional leading medical centers with significant experience in immuno-oncology, we now have five sites recruiting patients for this Phase 1 study. Patient enrollment is also on track and we expect to complete enrollment of both the monotherapy and dual combination dose escalation arms of the study this year."
The sites currently recruiting patients are: The START center in San Antonio, Texas; The University of Tennessee West Cancer Center in Memphis, Tennessee; Sarah Cannon Research Institute in Nashville, Tennessee; Massachusetts General Hospital in Boston, Massachusetts; and the University of Chicago in Chicago, Illinois. The study is expected to include up to ten sites and enroll approximately 140 patients.
Updated information on the COM701 Phase 1 clinical study will be next featured in a trial-in-progress poster at The AACR (Free AACR Whitepaper) Annual Meeting 2019 taking place March 29-April 3, 2019 at the Georgia World Congress Center, Atlanta, GA.
About the COM701 Phase 1 Study
This Phase 1 open-label clinical trial is designed to assess the safety and tolerability of administering escalating doses of COM701 monotherapy as well as combination administration with a PD-1 inhibitor in patients with advanced solid tumors. Additionally, the trial will evaluate evidence of preliminary antitumor activity of COM701 as a monotherapy as well as in combination with a PD-1 inhibitor in patients with selected tumor types, including non-small cell lung cancer, ovarian cancer, breast cancer and endometrial cancer. Additional information is available here.